GlassScriptPhysician profile
Themistocles Dassopoulos
NPI 1326083148
$22,178.63
in general payments reported to CMS, 2019-2025
41 companies · $8,456 in 2025
The $8,456 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $4,567 · 2021: $1,473 · 2022: $1,823 · 2023: $1,866 · 2024: $3,439 · 2025: $8,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,710 · Food and Beverage: $5,649 · Travel and Lodging: $1,393 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,710.00 |
| Food and Beverage | $5,649.20 |
| Travel and Lodging | $1,392.74 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $8,722.68 | 2019-2025 | Dificid, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,475.90 | 2019-2025 | Xifaxan |
| Abbvie INC. | $2,966.12 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Takeda Pharmaceuticals U.S.A., INC. | $2,138.41 | 2019-2025 | Entyvio, Gattex |
| Organon LLC | $507.85 | 2021-2025 | Renflexis, Hadlima |
| Celgene Corporation | $503.82 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $486.61 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $433.19 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $286.59 | 2019-2025 | Tremfya, Remicade, Stelara |
| Aimmune Therapeutics, INC. | $207.01 | 2024-2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.45 | 2019-2024 | |
| Lilly USA, LLC | $162.89 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $119.63 | 2024 | Vegzelma |
| Ethicon US, LLC | $119.15 | 2021-2025 | Echelon Circular, Echelon Endopath, Echelon Flex |
| Braintree Laboratories, INC. | $113.17 | 2021-2023 | Suflave |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $100.97 | 2022-2024 | Interstim |
| Boston Scientific Corporation | $82.36 | 2021-2025 | Enhance Transcarotid Peripheral Access Kit |
| Amgen INC. | $78.23 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $68.15 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $48.09 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $40.05 | 2022 | |
| Stryker Corporation | $35.96 | 2022 | |
| Shire North American Group INC | $31.34 | 2019 | |
| Integra Lifesciences Corporation | $31.10 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $28.18 | 2023 | |
| Mallinckrodt Hospital Products INC. | $27.24 | 2020 | |
| Avanos Medical | $22.10 | 2022 | |
| Intercept Pharmaceuticals, INC. | $21.37 | 2022 | |
| Ucb, INC. | $19.60 | 2019 | |
| Tela Bio, INC. | $19.33 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Astrazeneca Pharmaceuticals LP | $18.06 | 2023 | |
| Allergan, INC. | $17.90 | 2021 | |
| Kci USA, INC. | $17.25 | 2021 | |
| Endo Pharmaceuticals INC. | $13.26 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $11.62 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Themistocles Dassopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.